Athira Pharma Inc (ATHA)
$2.06
Insights on Athira Pharma Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 65.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 332.4%
Performance
- $2.02$2.20$2.06
1.89%
Downside
Day's Volatility :8.14%
Upside
6.36%
- $1.33$4.30$2.06
35.44%
Downside
52 Weeks Volatility :69.07%
Upside
52.09%
Returns
| Period | Athira Pharma Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -24.1% | -0.7% | 0.0% |
6 Months | 28.66% | 6.6% | 0.0% |
1 Year | -19.16% | 3.7% | -1.5% |
3 Years | -87.33% | 14.0% | -21.8% |
Highlights
Market Capitalization | 80.9M |
Book Value | $3.41 |
Earnings Per Share (EPS) | -3.09 |
Wall Street Target Price | 7.42 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -37.97% |
Return On Equity TTM | -64.42% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -126.1M |
Diluted Eps TTM | -3.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.24 |
EPS Estimate Next Year | -1.97 |
EPS Estimate Current Quarter | -0.96 |
EPS Estimate Next Quarter | -0.95 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 260.19%
Technicals Summary
Sell
Neutral
Buy
Athira Pharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Athira Pharma Inc | -15.26% | 28.66% | -19.16% | -87.33% | -87.67% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Athira Pharma Inc | NA | NA | NA | -3.24 | -0.64 | -0.38 | NA | 3.41 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Athira Pharma Inc | Buy | $80.9M | -87.67% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Perceptive Advisors LLC
14.10%Baker Bros Advisors LP
8.23%Vanguard Group Inc
4.43%Propel Bio Management LLC
3.89%Simplify Asset Management Inc.
3.89%BML Capital Management LLC
3.79%
Corporate Announcements
Athira Pharma Inc Earnings
Athira Pharma Inc’s price-to-earnings ratio stands at None
Read More
Company Information
m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer
Organization | Athira Pharma Inc |
Employees | 65 |
CEO | Dr. Mark J. Litton M.B.A., Ph.D. |
Industry | Commercial Services |
